Benzinga | Jun 3, 2021 08:22AM EDT

Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors

* Oric Pharmaceuticals Inc (NASDAQ:ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in advanced solid tumors.

* Data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

* As of the database cutoff date of April 21, the recommended dose of 160 mg of ORIC-101 was well-tolerated.

* Treatment-related adverse events were primarily mild or moderate, with only three severe events reported, all of which resolved with dose interruption.

* There were no treatment-related discontinuations and no requirement for prophylactic G-CSF at the RP2D.

* Five partial responses were observed, including one confirmed and four unconfirmed.

* Further evidence of antitumor activity was demonstrated by prolonged disease stabilization across multiple solid tumors.

* Notably, three of the four efficacy evaluable patients with relapsed pancreatic ductal adenocarcinoma demonstrated extended progression-free survival ranging from 3.6 months to 5.3+ months in the third-line or later setting, despite having already previously progressed on nab-paclitaxel.

* Enrollment in the expansion cohorts is ongoing, and updated data from the Phase 1b trial is expected in 2022.

* ORIC-101 is also being evaluated in a Phase 1b trial in combination with Xtandi (enzalutamide) in metastatic prostate cancer.

* Initial interim safety, efficacy, and translational data are expected in the second half of 2021.

* Price Action: ORIC shares closed at $21.5 on Wednesday.